ActiV.A.C.®

NEGATIVE PRESSURE WOUND THERAPY
ActiV.A.C.®
Designed for better wound care
49856_ActiVAC Tech Brochure_KCI.indd 2
6/2/09 9:53:56 AM
NEGATIVE PRESSURE WOUND THERAPY
Searching for better outcomes
Defining effective wound healing
Successful wound management in the community is the combination
of using the most effective wound-healing therapy with assuring
the highest possible patient quality of life outcome all in a
cost-effective manner.
Chronic
Diabetic Ulcers.
Pressure Ulcers.
Venous Leg Ulcers.
Acute
For patients moving
to home care.
The ability to get on with life is closely related to the degree of mobility a
therapy allows. Comfort and piece of mind require that the therapy is easy
to use and discrete to wear. All in all, the aim must be to offer the patient
their normal life in familiar surroundings.
� Complete mobility.
� Easy to use.
� Compact and discrete.
� Successful transitions from clinical to home care environment.
2
49856_ActiVAC Tech Brochure_KCI.indd 3
6/2/09 9:53:57 AM
Effective therapy
A growing body of clinical evidence demonstrates clearly that V.A.C.® (Vacuum Assisted Closure) Therapy
outperforms the use of wet to dry gauze and advanced moist wound dressings.1, 2 ActiVAC® is a next
generation system offering all the benefits of V.A.C.® Therapy in a simple, intuitive, easy-to-use package.
“Vacuum Assisted Closure
Therapy can be applied to
a wide variety of wounds,
improving the quality of life
of our patients.”
Louis C. Argenta, MD,
and Michael J. Morykwas,
PhD, USA
Case report: Chronic wound
Days
Wound upon initial
admission to a home
health agency.
63
6 weeks post
3 week follow-up:
2 weeks post
V.A.C.® Therapy initiation. V.A.C.® Therapy initiation: wound is completely
wound less than 50% of closed.
its original size.
A 70 year old female patient with a history of diabetes with peripheral neuropathy,
retinopathy, obesity and COPD. The patient had a non-healing diabetic ulcer on the
plantar surface of the right midfoot. This chronic diabetic ulcer had been present for
3 years. During this time various traditional and advanced wound care modalities were
tried but progress to closure was slow.
Case report: Acute wound
Days
Day 0 start
V.A.C.® Therapy
Patient released from
hospital to home after 8
weeks of therapy.
77
At home: after 1 week.
A total of 19 weeks of
V.A.C.® Therapy
treatment and the
wound is healed.
A 52 year old female patient, with 3 surgical wounds (due to removal of metastases)
hypertonia, angina pectoris, adipositis, type II diabetes, anus praeter, stoma, compartment
syndrome in both lower legs. 8 weeks in hospital, surgical wound treated with V.A.C.®
Therapy for rapid wound closure in order to prepare patient for chemotherapy.
1
Armstrong D.G, Lavery L.A., Negative
Pressure Wound Therapy after partial
diabetic foot amputation: a multicentre,
randomized controlled trial, Lancet 2005;
366:1704-1710.
2
Mouës C.M., van den Bemd G-J.C.M.,
Meerding W.J., Hovius S.E.R. An
economic evaluation of the use of TNP
on full-thickness wounds. Journal of
Wound Care 2005: 14: 224-227.
3
49856_ActiVAC Tech Brochure_KCI.indd 4
6/2/09 9:53:58 AM
Designed for better wound care
Searching for better wound care
ActiV.A.C.® is designed for complete mobility to ensure better outcomes in the
management of wounds for patients in the home or in the process of being
discharged from a clinical environment.
System elements
Ease and speed of use are greatly enhanced with features such as full
colour touch screens, electronic seal checking and settings guide.
� Intuitive software – touch screens and a fully re-programmed menu system.
Fast
Dressing application
� Click-fit canister application – for rapid, hygienic fitting and removal.
� Aural and visual application guidance system – distinctive alarms are
supported by clear on-screen guidance explaining the current problem
and illustrating the steps required for rapid rectification.
Drape application
Clinically proven V.A.C.® Therapy in a fully portable unit.
� Detailed course of therapy history recording – the unit automatically
logs therapy usage including therapy settings, duration and alarms.
SensaT.R.A.C.® application
Effective
� Anti-clog technology – the 3d multi-channel profile of SensaT.R.A.C.®
prevents blocking and clogging.
Therapy unit
The lightweight, portable design combined with Seal Check™ and
SensaT.R.A.C.® technology improve patient comfort and reduces distress.
� Long battery life for extended operation.
Mouës C.M., van den Bemd G-J.C.M.,
Meerding W.J., Hovius S.E.R. An
economic evaluation of the use of TNP
on full-thickness wounds. Journal of
Wound Care 2005: 14: 224-227.
4
The cost of pressure ulcers in the U.K.;
Bennett G, Dealey C, Posnett J, 2004:
Age and Ageing Vol. 33, No. 3: 230-235.
3
Quality
of Life
� Skin-soft conformable SensaT.R.A.C.® – the reticulated structure of the
pad presents a large surface area of even pressure to the wound, offering
a comfortable fit and minimises the risk of pressure damage to the skin.
� Odour control. The infection exudate management system controls
strong odours.
4
49856_ActiVAC Tech Brochure_KCI.indd 5
6/2/09 9:53:59 AM
e
V.A.C.® Therapy delivers lower hospitalisation costs and lower costs of
nursing time when compared with using moist gauze.3
� Cost effective – only 3% of wound management costs relate to
Cost
effective
dressings. The rest sits mostly in nursing time and hospital costs.4
The speed and efficacy of the Integrated V.A.C.® Therapy System cuts
these costs.
� Settings guide
� Detailed therapy
history report
� Seal Check™
� Clear on-screen alarm
explanations
5
49856_ActiVAC Tech Brochure_KCI.indd 6
6/2/09 9:53:59 AM
Designed to
keep you informed
System operation
Full colour touch screens and intuitive logical menus ensure that the Integrated V.A.C.® Therapy
System is simple to operate.
Simplified touch screen:
� Easy-to-use, intuitive, color screen
navigation.
� Single touch therapy on/off.
� Therapy setting confirmation screens.
Settings guide:
� Aligned with V.A.C.® Clinical Guidelines.
� Preset therapy settings by wound type.
� Step-by-step guide to therapy set-up.
Detailed therapy history report:
Therapy History
Date
Exit
Time
Event
Sept 04 2006 09:34:18
Unit On
Sept 04 2006 09:40:12
Therapy On
Sept 01 2006 14:46:49
Canister Changed
Sept 01 2006 14:16:48
Dressing Changed, 4
Sept 01 2006 14:15:44
Canister Full
Aug 29 2006 14:17:31
Therapy Off
Continuous
Therapy On
125mmHg
� Documents patient compliance.
� Allows clinicians to monitor and track:
� Therapy settings and alarm history
� Therapy dates and times
� Dressing and canister changes.
� Can be easily downloaded.
Seal Check™:
� Helps caregivers and patients identify and
troubleshoot negative pressure leaks.
� Provides real-time feedback with audio and
visual cues for leak location.
� May reduce unscheduled caregiver visits
due to better seal integrity.
6
49856_ActiVAC Tech Brochure_KCI.indd 7
6/2/09 9:54:00 AM
80
uit
Integrated System
development investment in products and services.
The
Integrated
Therapy System is a proven, non� Global library of clinical evidence,
with
30,000V.A.C.
patients
assisted world-wide every single invasive,
day. advanced approach to wound healing. The System
uses an intelligent therapy unit to deliver controlled negative
(sub-atmospheric) pressure to the wound site. Specialised
foam dressings, applied to the wound site, ensure
that fluid is continuously drawn away from
the wound and SensaT.R.A.C.®
Technology manages the equal
The Integrated V.A.C.® Therapy System is a proven, nondistribution of pressure across
invasive, advanced approach to wound healing. The System
the wound area.
usesTherapy
an intelligent
therapy
unit
to ulcers
deliver
controlled
V.A.C.
indications: Chronic
wounds
(pressure
and diabetic
wounds), negative
sub-acute wounds (surgical dehiscence, abdominal)
and acute wounds (traumatic wounds, partial-thickness burns, flaps and grafts).
(sub-atmospheric) pressure to the wound site. Specialised
V.A.C. Therapy contraindications: Contraindicated for patients with malignancy in the wound, untreated osteomyelitis, non-enteric and
foam dressings, applied to the wound site, ensure
unexplored fistulae, or necrotic tissue with eschar present. Do not place V.A.C. dressing over exposed blood vessels or organs.
that fluid is continuously drawn away
V.A.C. Therapy precautions: Precautions should be taken with patients with active bleeding, difficult wound haemostasis, or who are on
® from
anticoagulants.
Follow Universal
Precautions.
When
placing
the V.A.C.
dressing
in proximity
to blood® vesselsadvanced
or organs, take approach
care to ensure to
the
wound
SensaT.R.A.C.
The Integrated
V.A.C.
Therapy
System
is aand
proven,
non-invasive,
that they are adequately protected with overlying fascia, tissue or other protective barriers. Greater care should be taken with respect to
Technology
manages
thecould
equal
weakened,
or sutured
vessels or
organs.
fragments
or sharp
edges
puncture
a barrier,
vessel or organ. Wounds
woundirradiated
healing.
Theblood
System
uses
anBone
intelligent
therapy
unit
to
deliver
controlled
negative
®
TheTherapy.
Integrated
V.A.C.
Therapy
System
with enteric fistula require special precautions in order to optimise V.A.C.
Refer to the KCI
V.A.C. Therapy
Clinical Guidelines
for is a proven, nondistribution
of Specialised
pressure across
(sub-atmospheric)
pressure to the
wound site.
foam
dressings,
applied
the
more
user information.
invasive, advanced approach to woundtohealing.
The System
®
the wound
area.
wound site, ensure that fluid is continuously
drawn
away
from
the
wound
and
SensaT.R.A.C.
Therapy
Unit
uses an intelligent therapy unit to deliver controlled negative
Delivering
managed, across the wound area.
equal
distribution
of
pressure
©Technology
2007 KCI Licensing,manages
Inc. All Rights the
Reserved.
All trademarks
designated
herein
are property of KCI Licensing,
Inc, its affiliates
and licensors.
(sub-atmospheric)
pressure
to the
wound site. Specialised
®
Integrated System
®
Integrated System
®
®
®
®
®
®
measured, alarmed and
Those KCI trademarks designated with the “®” symbol are registered and those designated with “TM” are considered to be proprietary trademarks
recorded negative pressure.
or are pending trademark applications in at least one country where this product/work is commercialized. Most KCI products referred to herein are
subject to patents or patent applications.
foam dressings, applied to the wound site, ensure
that fluid is continuously drawn away from
®
the wound
and SensaT.R.A.C.
“The interface
foam
Technology
the equal
dressingmanages
may actually
distribution
of
pressure
across
be critical in the
the
wound
area.
transmission of pressure”
The Integrated V.A.C.® Therapy System is a proven, nonTherapy Unit
invasive, advanced approach to wound healing. The System
Ref: Banwell P, Teot L
Delivering managed, measured,
uses an intelligent therapy unit to deliver controlled negative
alarmed and recorded negative
(2006): Topical negative
(sub-atmospheric) pressure to the wound site. Specialised
pressure.
pressure (TNP): the
SensaT.R.A.C.
foam dressings,
applied to the wound site, ensure
evolution
Foam Dressings
Intelligent
technologyof
to a novel
that
fluid
is maintain
continuously
drawn away from
monitortherapy,
and
even
Sizes, shapes and
Journal
of Tissue
pressure
wound site.
formulations to suit
theat the
wound
and SensaT.R.A.C.®
Viability; 16(1): 1.
all wound types.
Therapy Unit
Technology manages the equal
Delivering managed,
distribution of pressure across
measured, alarmed and
the wound area.
recorded negative pressure.
The Integrated V.A.C.® Therapy System is a proven, nonV.A.C. GranuFoam Silver is only available
invasive, advanced approach to
wound
healing. The System
in certain
countries.
SensaT.R.A.C.
uses an intelligent therapy unit to deliver controlled negative
Intelligent technology to
pressure to the wound site. Specialised
monitor and maintain(sub-atmospheric)
even
pressure at the wound site.
foam dressings, applied to the wound site, ensure
that fluid is continuously drawn away from
the wound and SensaT.R.A.C.®
Technology manages the equal
Therapy Unit
Delivering managed,
distribution of pressure across
measured, alarmed and
the wound area.
SensaT.R.A.C.
recorded negative pressure.
Integrated System
®
Integrated System
*
®
®
®
Foam Dressings
Sizes, shapes and
formulations to suit
all wound types.
Intelligent technology to
monitor and maintain even
pressure at the wound site.
Therapy Unit
Delivering managed,
measured, alarmed and
recorded negative pressure.
Foam Dressings
Sizes, shapes and
formulations to suit
all wound types.
Foam Dressings
Sizes, shapes and
formulations to suit
all wound types.
49856_ActiVAC Tech Brochure_KCI.indd 8
SensaT.R.A.C.®
Intelligent technology to
monitor and maintain even
pressure at the wound site.
www.kci-medical.com
KCI INTERNATIONAL HEAD OFFICE
KCI Europe Holding B.V.
Parktoren, 6th Floor
Van Heuven Goedhartlaan 11
PO Box 129
1180 AC Amstelveen
The Netherlands
Tel +31 (0) 20 426 0000
Fax +31 (0) 20 426 0099
www.kci-medical.com
UNITED KINGDOM
KCI Medical Ltd.
KCI House
Langford Business Park ·
Langford Locks
Kidlington OX5 1GF
United Kingdom
24h Cust. Service +44 (0) 800 980 8880
Phone +44 (0)1865 840 600
Fax
+44 (0)1865 840 626
www.kci-medical.com
“The interface foam
KCI Medical Products (UK) Ltd.
dressing
may actually
11 Nimrod Way
Ferndown Industrial Estate
be
critical
in the
Wimborne, Dorset
BH21 7SH
United Kingdom of pressure”
transmission
Phone +44 (0)1202 654 100
Fax +44 (0)1202 654 140
www.kci-medical.com
Ref: Banwell P, Teot L
KCI UK Holdings
Ltd.negative
(2006):
Topical
1st Floor 3 Cedar Park
pressure
(TNP):
the
Cobham Road
Ferndown Industrial
evolution
of a Estate
novel
Wimborne, Dorset BH21 7SB
therapy,
Journal of Tissue
United Kingdom
Phone +44 (0) 1202 866 400
Viability;
16(1):
1.408
Fax
+44 (0)
1202 866
www.kci-medical.com
“The interface foam
dressing may actually
be critical in the
transmission of pressure”
Ref: Banwell P, Teot L
(2006): Topical negative
pressure (TNP): the
evolution of a novel
therapy, Journal of Tissue
“The16(1):
interface
Viability;
1. foam
dressing may actually
be critical in the
transmission of pressure”
KCII 1048-08-07-EN
Ref: Banwell P, Teot L
(2006): Topical negative
pressure (TNP): the
evolution of a novel
therapy, Journal of Tissue
“The interface foam
Viability; 16(1): 1.
dressing may actually
be critical in the
transmission of pressure”
Ref: Banwell P, Teot L
(2006): Topical negative
pressure (TNP): the
evolution of a novel
therapy, Journal of Tissue
Viability; 16(1): 1.
SensaT.R.A.C.®
Intelligent technology to
monitor and maintain even
pressure at the wound site.
6/2/09 9:54:05 AM
�
�
V
a
V
u
V
a
t
w
w
m
©
T
o
s
KCI: Your global partner
The global medical technology company with leadership
positions in advanced wound care and therapeutic surfaces.
Our service has been designed, to maximise the capability of
our customers to deliver better wound care.
KCI
Corporate
GLOBAL
HEADOffice
OFFICE
8023
Vantage Drive
KCI International
San
8023Antonio
Vantage Drive
TX
San78230
Antonio
U.S.A.
TX 78230
TU.S.A.
(free) 1 800 531 5396, extension 6335
Tel
+1 1210
T(free)
800255
5316335
5396, extension 6335
Fax
210210
255255
6991
Tel +1 +1
6335
www.kci1.com
Fax
+1 210 255 6991
www.kci-medical.com
KCI Europe Holding B.V.
Parktoren, 6th Floor
KCI INTERNATIONAL
HEAD
Van
Heuven Goedhartlaan
11 OFFICE
KCIBox
Europe
PO
129 Holding B.V.
Parktoren,
6th Floor
1180
AC Amstelveen
Van Netherlands
Heuven Goedhartlaan 11
The
PO Box
Tel
+31129
(0) 20 426 0000
1180+31
AC(0)
Amstelveen
Fax
20 426 0099
The Netherlands
www.kci-medical.com
Tel
+31 (0) 20 426 0000
Fax Medical
+31 (0)Australia
20 426 0099
KCI
Pty Ltd.
www.kci-medical.com
Level 7
15 Orion Road
Lane Cove West NSW 2066
UNITED KINGDOM
Australia
KCI Medical
Ltd.
General
Administration
KCI House
Tel
+61 (0) 2 9422 4322
Langford
Business
·
Fax
+61 (0)
2 9422Park
4344
Langford
Locks815 529
Toll
Free 1800
Kidlington Service
OX5 1GF
Customer
& Orders
United
Kingdom
Tel
1300
KCI VAC (1300 524 822)
24h 1800
Cust. KCI
Service
(0) 524
800 822)
980 8880
Fax
VAC+44
(1800
Phone +44 (0)1865 840 600
www.kci-medical.com
Fax
+44 (0)1865 840 626
www.kci-medical.com
KCI Medical Products (UK) Ltd.
11 Nimrod Way
Ferndown Industrial Estate
Wimborne, Dorset BH21 7SH
United Kingdom
Phone +44 (0)1202 654 100
Fax
+44 (0)1202 654 140
www.kci-medical.com
KCI UK Holdings Ltd.
1st Floor 3 Cedar Park
Cobham Road
Ferndown Industrial Estate
Wimborne, Dorset BH21 7SB
United Kingdom
Phone +44 (0) 1202 866 400
Fax
+44 (0) 1202 866 408
www.kci-medical.com
� A comprehensive programme of introductory training and
ongoing education.
� 24-hour customer service to address real-time requirements.
� Assured best practice, with continued research and
development investment in products and services.
� Global library of clinical evidence, with 30,000 patients
assisted world-wide every single day.
V.A.C.® Therapy indications: Chronic wounds (pressure ulcers and diabetic wounds), sub-acute wounds (surgical dehiscence, abdominal)
and acute wounds (traumatic wounds, partial-thickness burns, flaps and grafts).
V.A.C.® Therapy contraindications: Contraindicated for patients with malignancy in the wound, untreated osteomyelitis, non-enteric and
unexplored fistulae, or necrotic tissue with eschar present. Do not place V.A.C.® dressing over exposed blood vessels or organs.
V.A.C.® Therapy precautions: Precautions should be taken with patients with active bleeding, difficult wound haemostasis, or who are on
anticoagulants. Follow Universal Precautions. When placing the V.A.C.® dressing in proximity to blood vessels or organs, take care to ensure
that they are adequately protected with overlying fascia, tissue or other protective barriers. Greater care should be taken with respect to
weakened, irradiated or sutured blood vessels or organs. Bone fragments or sharp edges could puncture a barrier, vessel or organ. Wounds
with enteric fistula require special precautions in order to optimise V.A.C.® Therapy. Refer to the KCI V.A.C.® Therapy Clinical Guidelines for
more user information.
© 2007 KCI Licensing, Inc. All Rights Reserved. All trademarks designated herein are property of KCI Licensing, Inc, its affiliates and licensors.
Those KCI trademarks designated with the “®” symbol are registered and those designated with “TM” are considered to be proprietary trademarks
or are pending trademark applications in at least one country where this product/work is commercialized. Most KCI products referred to herein are
subject to patents or patent applications.
KCII 1050-07-07-EN
49856_ActiVAC Tech Brochure_KCI.indd 1
6/2/09 9:53:56 AM